CC
TNGX icon

Casdin Capital’s Tango Therapeutics TNGX Stock Holding History

Casdin Capital’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125,000
Closed -$171K – 42
2025
Q1 		$171K Sell
125,000
-1,063,349
-89% -$2.61M 0.01% 43
2024
Q4 		$3.67M Hold
1,188,349
– – 0.24% 32
2024
Q3 		$9.15M Hold
1,188,349
– – 0.61% 23
2024
Q2 		$10.2M Hold
1,188,349
– – 0.78% 23
2024
Q1 		$9.44M Hold
1,188,349
– – 0.7% 25
2023
Q4 		$11.8M Sell
1,188,349
-119,000
-9% -$1.03M 1.15% 19
2023
Q3 		$14.7M Buy
1,307,349
+307,349
+31% +$1.87M 1.63% 17
2023
Q2 		$3.32M Hold
1,000,000
– – 0.29% 33
2023
Q1 		$3.95M Buy
+1,000,000
New +$5.8M 0.33% 35
2022
Q3 		– Sell
-3,500,000
Closed -$15.9M – 44
2022
Q2 		$15.9M Sell
3,500,000
-1,987,910
-36% -$12M 1.34% 21
2022
Q1 		$41.6M Hold
5,487,910
– – 1.87% 23
2021
Q4 		$60M Hold
5,487,910
– – 1.69% 21
2021
Q3 		$71M Buy
+5,487,910
New +$65.8M 1.77% 24

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Casdin Capital's TNGX Position: Q2 2025 in Review

Casdin Capital sold out of Tango Therapeutics (TNGX) in Q2 2025, closing a stake of 125,000 shares — an estimated $171K sold.

Casdin Capital first reported a position in TNGX in Q3 2021 and held it in 13 quarters. The position peaked at $71M in Q3 2021. 115 funds tracked by Wall St. Rank hold TNGX as of Q2 2025.

  • Casdin Capital reported no remaining Tango Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Casdin Capital sold 125,000 Tango Therapeutics shares in Q2 2025, an estimated $171K.
  • Casdin Capital first reported a position in Tango Therapeutics in Q3 2021 and held it in 13 quarters.
  • Casdin Capital's Tango Therapeutics position peaked at $71M in Q3 2021.
  • 115 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2025.

Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.